Mason Carrico
Stock Analyst at Stephens & Co.
(3.66)
# 610
Out of 5,127 analysts
77
Total ratings
48.53%
Success rate
8.71%
Average return
Main Sectors:
Stocks Rated by Mason Carrico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTRA Natera | Maintains: Overweight | $197 → $235 | $211.65 | +11.03% | 6 | Nov 13, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Overweight | $1.8 → $2 | $1.81 | +10.50% | 6 | Nov 10, 2025 | |
| HOLX Hologic | Downgrades: Equal-Weight | $78 → $76 | $75.15 | +1.13% | 6 | Oct 22, 2025 | |
| NEO NeoGenomics | Maintains: Overweight | $6.5 → $11 | $11.50 | -4.35% | 2 | Sep 2, 2025 | |
| VCEL Vericel | Reiterates: Overweight | $67 | $35.59 | +88.26% | 3 | Jun 16, 2025 | |
| ILMN Illumina | Reiterates: Overweight | $105 | $119.32 | -12.00% | 8 | May 20, 2025 | |
| TXG 10x Genomics | Reiterates: Overweight | $14 | $19.15 | -26.89% | 6 | May 15, 2025 | |
| CDNA CareDx | Reiterates: Overweight | $40 | $20.57 | +94.46% | 10 | May 5, 2025 | |
| GKOS Glaukos | Maintains: Overweight | $140 → $115 | $113.03 | +1.74% | 1 | May 2, 2025 | |
| VCYT Veracyte | Reiterates: Overweight | $45 | $37.03 | +21.52% | 7 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $55 | $105.03 | -47.63% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $4.31 | +39.21% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $17.30 | -1.73% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $52 | $72.58 | -28.35% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $20 | $5.08 | +293.70% | 4 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $41 | $32.37 | +26.66% | 7 | Jan 2, 2025 |
Natera
Nov 13, 2025
Maintains: Overweight
Price Target: $197 → $235
Current: $211.65
Upside: +11.03%
Pacific Biosciences of California
Nov 10, 2025
Maintains: Overweight
Price Target: $1.8 → $2
Current: $1.81
Upside: +10.50%
Hologic
Oct 22, 2025
Downgrades: Equal-Weight
Price Target: $78 → $76
Current: $75.15
Upside: +1.13%
NeoGenomics
Sep 2, 2025
Maintains: Overweight
Price Target: $6.5 → $11
Current: $11.50
Upside: -4.35%
Vericel
Jun 16, 2025
Reiterates: Overweight
Price Target: $67
Current: $35.59
Upside: +88.26%
Illumina
May 20, 2025
Reiterates: Overweight
Price Target: $105
Current: $119.32
Upside: -12.00%
10x Genomics
May 15, 2025
Reiterates: Overweight
Price Target: $14
Current: $19.15
Upside: -26.89%
CareDx
May 5, 2025
Reiterates: Overweight
Price Target: $40
Current: $20.57
Upside: +94.46%
Glaukos
May 2, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $113.03
Upside: +1.74%
Veracyte
Mar 26, 2025
Reiterates: Overweight
Price Target: $45
Current: $37.03
Upside: +21.52%
Mar 26, 2025
Reiterates: Overweight
Price Target: $55
Current: $105.03
Upside: -47.63%
Mar 19, 2025
Reiterates: Overweight
Price Target: $6
Current: $4.31
Upside: +39.21%
Mar 18, 2025
Reiterates: Equal-Weight
Price Target: $17
Current: $17.30
Upside: -1.73%
Mar 6, 2025
Reiterates: Overweight
Price Target: $52
Current: $72.58
Upside: -28.35%
Jan 16, 2025
Reiterates: Equal-Weight
Price Target: $20
Current: $5.08
Upside: +293.70%
Jan 2, 2025
Reiterates: Overweight
Price Target: $41
Current: $32.37
Upside: +26.66%